84 results about "Afferent" patented technology

A dual electrode arrangement, is provided, wherein two, preferably unidirectional, electrode configurations flank a nerve junction from which a preselected nerve branch issues, proximally and distally to the junction, with respect to the brain. The arrangement is conducive to the following: generating efferent action-potential propagations, substantially restricted to the preselected nerve branch, inhibiting afferent action-potential propagations, from the preselected nerve branch, selectively generating action-potential propagations, in a subset of nerve fibers of a predetermined diameter range, substantially restricted to the preselected nerve branch, and selectively inhibiting action-potential propagations, in a subset of nerve fibers of a predetermined diameter range, substantially restricted to the preselected nerve branch. The dual electrode arrangement is further conducive to monitoring naturally-occurring, efferent action-potential propagations, heading towards the preselected nerve branch, and monitoring naturally-occurring, afferent action-potential propagations, from the preselected nerve branch. The unidirectional electrode configurations may be monopolar, bipolar, tripolar, or multipolar. Communication with extracorporeal stations, and closed loop operations are also provided.

A generally spherical vascular remodeling device is permanently positionable at a junction of afferent and efferent vessels of a bifurcation having an aneurysm. After positioning the device at the junction to substantially conform the device to the shape of the junction, the device acts as a scaffolding to inhibit herniation of objects out of the aneurysm and the device permits perfusion to the efferent vessels. Positioning the device may include deployment and mechanical or electrolytic release from a catheter. Embolic material may be inserted in the aneurysm before or after positioning the device. The device may have a first end, a second end substantially opposite to the first end, and a plurality of filaments extending between and coupled at the first end and the second end. Such devices may be football shaped, pumpkin shaped, or twisted. The device may include a plurality of loops forming a generally spherical shape.

A dual electrode arrangement, is provided, wherein two, preferably unidirectional, electrode configurations flank a nerve junction from which a preselected nerve branch issues, proximally and distally to the junction, with respect to the brain. The arrangement is conducive to the following: generating efferent action-potential propagations, substantially restricted to the preselected nerve branch, inhibiting afferent action-potential propagations, from the preselected nerve branch, selectively generating action-potential propagations, in a subset of nerve fibers of a predetermined diameter range, substantially restricted to the preselected nerve branch, and selectively inhibiting action-potential propagations, in a subset of nerve fibers of a predetermined diameter range, substantially restricted to the preselected nerve branch. The dual electrode arrangement is further conducive to monitoring naturally-occurring, efferent action-potential propagations, heading towards the preselected nerve branch, and monitoring naturally-occurring, afferent action-potential propagations, from the preselected nerve branch. The unidirectional electrode configurations may be monopolar, bipolar, tripolar, or multipolar. Communication with extracorporeal stations, and closed loop operations are also provided.

A method and apparatus for treatment of an eating disorder includes electrically, mechanically and / or pharmaceutically / chemically stimulating a of the vagus nerve of the lower esophagus, cardia, esophageal / cardia junction, cardia / fundus junction or upper stomach so as to induce afferent action potentials on the vagus nerve. The device may be noninvasively adjusted after implantation to provide increased or decreased restriction on the patient's gastrointestinal tract. Each stimulus may be administered as a series of programmed pulses of defined amplitude, duration and period, to evoke a responsive signal to the brain by the target nerve, effective for producing a temporary feeling of satiety in the person. An implantable stimulus generator may be operatively coupled to a nerve electrode, pressure device or chemical outlet to apply a defined signal to a selected nerve branch. The implantable stimulus generator is programmable to allow clinician programming of defined signal parameters effective to treat the eating disorder of the patient. Methods are also provided to identify electrodes nearest to a branch of the vagus nerve to apply an electrical stimulation signal with improved efficiency.

The present invention is an apparatus and method for controlling blood pressure by stimulating the cardiac afferent sympathetic nerves. The invention may be implemented in a medical device having a pressure sensor for sensing blood pressure, an electrode for providing electrical signals to the cardiac afferent sympathetic nerves, and a controller for providing signals to the electrode as a function of blood pressure signals received from the pressure sensor.

A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particularly chronic pain.

A method, apparatus, and surgical technique for the modulation of autonomic function, for the purpose of treating any of several conditions and diseases, including obesity, metabolic disorders, endocrine disorders, diabetes, respiratory disease, asthma, inflammatory disease, immunological disease, infection, cancer, cardiac disease, cardiovascular disease, cerebrovascular disease, stroke, vasospasm, vascular disease, psychiatric disease, depression, affective disorders, anxiety disorders, and other conditions. This includes neural and tissue modulators, including implanted devices, used to modulate efferent and afferent autonomic neurons to influence or control autonomic or other neural function, including modulation of sympathetic and parasympathetic nervous system components as well as their combination.

Described herein are vascular remodeling devices that include a proximal section, an intermediate section, and a distal section. During deployment, the proximal section can expand from a compressed delivery state to an expanded state and anchors the device in an afferent vessel of a bifurcation. The distal section expands from the compressed delivery state to an expanded state that may be substantially planar, approximately semi-spherical, umbrella shaped, or reverse umbrella shaped. The distal section is positioned in a bifurcation junction across the neck of an aneurysm or within an aneurysm. The intermediate section allows perfusion to efferent vessels. Before or after the device is in position, embolic material may be used to treat the aneurysm. The distal section can act as a scaffolding to prevent herniation of the embolic material. The device can be used for clot retrieval with integral distal embolic protection.

A non-invasive vagal stimulation device and method. The device comprises a body having a vibration member. The stimulation is created by the vibration member which has a vibratory rate that can be adjusted from being off to a preferred operating range. The non-invasive stimulation method consists of placing the non-invasive stimulation device in the vicinity of the carotid artery bifrication where arises a carotid sinus and body which contain afferent sensory nerves that travel to medulla oblongata of brain, and either applying pressure in place, or moving the device along the target arm. The method can be accomplished either with the vibration feature of the device turned on or off.

A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particular chronic pain.

A method and apparatus for treatment of an eating disorder includes electrically stimulating the vagus nerve of the lower esophagus, cardia, esophageal / cardia junction, cardia / fundus junction or upper stomach so as to induce afferent action potentials on the vagus nerve. A device comprising a gastric band including stimulation electrodes may be noninvasively adjusted after implantation to provide increased or decreased restriction on the patient's gastrointestinal tract. Each stimulus may be administered as a series of programmed pulses of defined amplitude, duration and period, to evoke a responsive signal to the brain by the target nerve, effective for producing a temporary feeling of satiety in the person. A programmable implantable stimulus generator may be operatively coupled to a nerve electrode. Methods are also provided to identify electrodes nearest to a branch of the vagus nerve to apply an electrical stimulation signal with improved efficiency.

A method and apparatus for treatment of an eating disorder includes electrically, mechanically and / or pharmaceutically / chemically stimulating a of the vagus nerve of the lower esophagus, cardia, esophageal / cardia junction, cardia / fundus junction or upper stomach so as to induce afferent action potentials on the vagus nerve. The device may be noninvasively adjusted after implantation to provide increased or decreased restriction on the patient's gastrointestinal tract. Each stimulus may be administered as a series of programmed pulses of defined amplitude, duration and period, to evoke a responsive signal to the brain by the target nerve, effective for producing a temporary feeling of satiety in the person. An implantable stimulus generator may be operatively coupled to a nerve electrode, pressure device or chemical outlet to apply a defined signal to a selected nerve branch. The implantable stimulus generator is programmable to allow clinician programming of defined signal parameters effective to treat the eating disorder of the patient. Methods are also provided to identify electrodes nearest to a branch of the vagus nerve to apply an electrical stimulation signal with improved efficiency.

The invention relates to a device for urinary catheterisation comprising a catheter element and a pharmaceutically active composition containing a hormone, an efferent blocking agent, an afferent blocking agent and / or a sympathomimetic agent, the catheter element being adapted to deliver the pharmaceutically active composition in the lower urinary tract system during catheterisation. The invention also relates to the use of said pharmaceutically active composition for the manufacture of a device for the treatment, alleviation or prophylaxis of incontinence in a human and to a method of treating a human suffering from or being susceptible to incontinence. The invention further relates to a device for urinary catheterisation comprising a discrete unit dose comprising a pharmaceutically active composition and a catheter element adapted to shed said pharmaceutically active composition in the lower urinary tract system during catheterisation.

Systems and Methods treat bladder dysfunctions using neuromodulation stimulation. Bladder emptying through stimulation of urethral afferents, and continence through stimulation of the dorsal genital nerve, is provided with one or more implanted pulse generators and one or more leads. A simple surgical procedure preserves all existing functions. A stimulating catheter is provided to be used as a clinical screening tool. The stimulating catheter is used to measure bladder pressures and stimulate the urethra at the same time.

A device is for the electrotherapeutic treatment of headaches such as tension headaches and migraines. An electrode support (10) has a shape and is size selected so as to allow, independently from the subject, the excitation of the afferent paths of the supratrochlear (2) and supraorbital (3) nerves of the ophthalmic branch (1) of the trigeminal nerve. An electrical circuit includes a programmable signal generator suitable for creating pulses of a duration of between 150 and 450 microseconds with a maximum increase in intensity of 0 to 20 milliamperes at a rate of less than or equal to 40 microamperes per second and with a step up in intensity not exceeding 50 microamperes.